The Global Pharmaceutical R&D Directory provides a wealth of key business data on trends in pharmaceutical research. At a time when investment in R&D is at an all-time high, this essential publication is intended as a strategic reference guide to the important trends in pharmaceutical R&D, as well as providing the means to benchmark your company's performance.
From an examination of global R&D investment and productivity to a breakdown of R&D trends in every major therapeutic class, The R&D Directory provides a comprehensive review of the current R&D environment.
Packed with facts, personalities, charts, and statistics, it is presented as a book and also as a fully searchable PDF edition and CD-ROM.
From an examination of global R&D investment and productivity to a breakdown of R&D trends in every major therapeutic class, The R&D Directory provides a comprehensive review of the current R&D environment.
The R&D Directory provides essential time-saving business information on:
- The development pipeline of major companies is analyzed by therapeutic categories and stages
- Compounds in research by therapeutic class for major companies
- Number of licensed compounds by therapeutic class and development stage
- Comparison of companies' licensed/originated product pipelines
- Average development time to market, and attrition data
- Trends in global R&D investment, cost, and culture
- Number of biotechnology products by development phase, therapeutic class, and type
- Plus much, much more!
Key Features:
- Trends in licensing for major pharmaceutical companies
- R&D Focus for key therapy areas
- Benchmark development time by phase and success for over dozens of therapeutic categories
- Comparisons of compounds in research by development stage for dozens of therapeutic areas
- Analysis of previous year’s pipeline development by stage for all major pharmaceutical companies worldwide.
Contents:
- Section 1 & 2 of The R&D Directory looks at the trends in R&D expenditure in the major markets, changes in employment patterns and productivity levels in relation to pharmaceutical sales.
- Section 3 reviews the outsourcing industry and examines its role in pharmaceutical R&D.
- Sections 4 to 9 analyse the trends in R&D by examining the therapeutic focus of selected companies, preclinical compounds, biotechnology compounds, compounds in clinical development for every major therapy class, and licensing activities.
- Section 10 provides extensive attrition and time-in-development data for the major therapeutic categories.
Coverage:
- Western & Eastern Europe incl. UK
- USA & Canada
- South & Central America
- The Middle East
- All of Africa
- All of Asia, including China, India, and Japan
- Australia & New Zealand.
Packed with facts, personalities, charts, and statistics, it is presented as a book and also as a fully searchable PDF edition and CD-ROM.
Table of Contents
- Introduction
- Content Pages
- In-depth Profiles
- Indexes
